{"id":2606,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2004-02-03","marketCap":21.31011962890625,"name":"Oncternal Therapeutics Inc","phone":"18584341113","outstanding":58.970001220703125,"symbol":"ONCT","website":"https://www.oncternal.com/","industry":"Biotechnology"},"price":6.9675,"year":2024,"month":1,"day":9,"weekday":"Tuesday","title":"The Impact of Global Trade Policies and Tariffs on Oncternal Therapeutics Inc Stock and Industry Peers","date":"2024-01-09","url":"/posts/2024/01/09/ONCT","content":[{"section":"Introduction","text":"Global trade policies and tariffs can have a significant impact on the stock performance of companies, including Oncternal Therapeutics Inc, and the broader industry. These policies and tariffs, which are implemented by governments to regulate international trade, can influence the demand, supply, and price dynamics of goods and services. The impact on Oncternal Therapeutics Inc and its industry peers depends on various factors such as the company's exposure to international markets, the nature of its products, and its ability to adapt to changing trade dynamics."},{"section":"Effects of Trade Policies","text":"Trade policies, such as import restrictions or export subsidies, can affect Oncternal Therapeutics Inc and its industry peers in several ways. Firstly, policies that impose import restrictions on certain goods or raw materials can disrupt the supply chain of the company, leading to increased costs and potential delays in production. This can negatively impact the stock performance of Oncternal Therapeutics Inc if it relies heavily on imported materials or components. Secondly, trade policies can influence the competitiveness of domestic industries. Tariffs or trade barriers imposed on foreign competitors can provide a competitive advantage to Oncternal Therapeutics Inc and its industry peers by limiting the entry of foreign competitors or increasing their costs. This can potentially lead to increased market share and improved profitability for the company."},{"section":"Impact of Tariffs","text":"Tariffs are taxes imposed on imported goods and services, and they can have both direct and indirect effects on Oncternal Therapeutics Inc and its industry peers. Directly, tariffs can increase the cost of imported raw materials, components, or finished goods, making them more expensive for the company. This can reduce the company's profitability if it cannot pass on the increased costs to consumers. Indirectly, tariffs can lead to retaliatory actions from other countries, resulting in a trade war. Trade wars can disrupt global supply chains, increase uncertainty, and negatively impact stock markets, including the stock performance of Oncternal Therapeutics Inc and its industry peers."},{"section":"Trade Dynamics and Adaptability","text":"The impact of global trade policies and tariffs on Oncternal Therapeutics Inc and its industry peers also depends on their ability to adapt to changing trade dynamics. Companies that are well-diversified in terms of markets, suppliers, and products may be better positioned to withstand trade disruptions. For example, if Oncternal Therapeutics Inc has a strong presence in multiple international markets, it may be able to mitigate the impact of trade policies or tariffs in specific regions by focusing on other markets. Similarly, companies that have alternative suppliers or can source materials locally may be less affected by import restrictions or tariffs. The adaptability and resilience of Oncternal Therapeutics Inc and its industry peers in the face of changing trade dynamics play a crucial role in determining their stock performance."},{"section":"Conclusion","text":"In conclusion, global trade policies and tariffs can have a significant impact on Oncternal Therapeutics Inc stock and its industry peers. Import restrictions, export subsidies, and tariffs can disrupt supply chains, affect competitiveness, and increase costs for the company. Additionally, trade wars resulting from tariffs can create further uncertainty and negatively impact stock markets. However, the impact also depends on the adaptability and resilience of Oncternal Therapeutics Inc and its industry peers in navigating changing trade dynamics. Companies that are well-diversified and can adapt to trade disruptions may be better positioned to mitigate the negative effects and potentially even benefit from certain trade policies. Investors should carefully monitor global trade developments and assess the specific exposure and adaptability of Oncternal Therapeutics Inc and its industry peers."}],"tags":["CrossOver21","Long","Biotechnology"],"news":[{"category":"company","date":1704722400,"headline":"Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer","id":124926389,"image":"https://media.zenfs.com/en/globenewswire.com/884d79fc166c08d7bc89cb2d1d807727","symbol":"ONCT","publisher":"Yahoo","summary":"SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the fourth patient has now been enrolled into its Phase 1/2 study of ONCT-534, its dual-action androgen receptor inhibitor, for the treatment of patients with advanced prostate cancer who are relapsed or refractory to approved androgen receptor pathway inhibitors (ARPI). The last two patie","url":"https://finance.yahoo.com/news/oncternal-therapeutics-enrolls-patients-third-140000306.html"},{"category":"company","date":1704702120,"headline":"Oncternal enrolls patients into third dosing cohort of Phase 1/2 trial","id":124940668,"image":"","symbol":"ONCT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3290016249"},{"category":"company","date":1704437400,"headline":"Oncternal Therapeutics trading halted, news pending","id":124898503,"image":"","symbol":"ONCT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3287311182"},{"category":"company","date":1704376800,"headline":"Oncternal Therapeutics Announces Reverse Stock Split","id":124857898,"image":"https://media.zenfs.com/en/globenewswire.com/884d79fc166c08d7bc89cb2d1d807727","symbol":"ONCT","publisher":"Yahoo","summary":"SAN DIEGO, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that its board of directors (Board) has approved a 1-for-20 reverse stock split of the company's common stock. The reverse stock split will become effective at 12:01 a.m. Eastern time on January 8, 2024. The company's common stock is expected to begin trading on a split-adjusted basis on The Na","url":"https://finance.yahoo.com/news/oncternal-therapeutics-announces-reverse-stock-140000210.html"},{"category":"company","date":1704356100,"headline":"Oncternal Therapeutics announces a reverse stock split","id":124860398,"image":"","symbol":"ONCT","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3284471821"},{"category":"company","date":1704355560,"headline":"Oncternal Therapeutics to effect 1-for-20 reverse stock split","id":124860399,"image":"","symbol":"ONCT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3284460950"},{"category":"company","date":1704204000,"headline":"Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)","id":124804125,"image":"https://media.zenfs.com/en/globenewswire.com/884d79fc166c08d7bc89cb2d1d807727","symbol":"ONCT","publisher":"Yahoo","summary":"SAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the approval of an inducement award to one new employee, Rebecca Nolan-Olson, who is joining Oncternal as Safety Manager. The award will be made on January 2, 2024 under Oncternalâ€™s 2021 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employee","url":"https://finance.yahoo.com/news/oncternal-therapeutics-reports-inducement-award-140000179.html"},{"category":"company","date":1704182820,"headline":"Oncternal Therapeutics reports inducement award under Nasdaq listing rule","id":124815843,"image":"","symbol":"ONCT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3281135217"},{"category":"company","date":1703661480,"headline":"Why Ascent Industries Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket","id":124723486,"image":"","symbol":"ONCT","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3274409063"},{"category":"company","date":1703654460,"headline":"Analysts Are Bullish on These Healthcare Stocks: Coherus Biosciences (CHRS), Oncternal Therapeutics (ONCT)","id":124733537,"image":"","symbol":"ONCT","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3274325703"},{"category":"company","date":1703639700,"headline":"Why Reneo Pharmaceuticals Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session","id":124727474,"image":"","symbol":"ONCT","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3274730247"},{"category":"company","date":1703599200,"headline":"Oncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma","id":124716317,"image":"https://media.zenfs.com/en/globenewswire.com/884d79fc166c08d7bc89cb2d1d807727","symbol":"ONCT","publisher":"Yahoo","summary":"SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today updated the status of its dose escalation/dose expansion Phase 1/2 Study ONCT-808-101, evaluating the companyâ€™s ROR1-targeting autologous CAR T cell therapy ONCT-808 for the treatment of patients with relapsed or refractory aggressive B-cell lymphoma, including patients who have failed previous CD19 CAR","url":"https://finance.yahoo.com/news/oncternal-therapeutics-updates-status-phase-140000936.html"},{"category":"company","date":1703595120,"headline":"Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session","id":124711343,"image":"","symbol":"ONCT","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3273516828"},{"category":"company","date":1703589840,"headline":"Crude Oil Rises Over 3%; US Home Prices Increase In October","id":124710797,"image":"","symbol":"ONCT","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3273443282"},{"category":"company","date":1703585280,"headline":"Oncternal slips after early data for lymphoma therapy","id":124711270,"image":"","symbol":"ONCT","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3273381367"},{"category":"company","date":1703580240,"headline":"Dow Gains Over 50 Points; Chicago Fed National Activity Index Increases For November","id":124710667,"image":"","symbol":"ONCT","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3273315426"},{"category":"company","date":1703577840,"headline":"Oncternal Therapeutics provides update on Phase 1/2 study of lymphoma candidate","id":124711273,"image":"","symbol":"ONCT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3273285528"},{"category":"company","date":1703561520,"headline":"12 Health Care Stocks Moving In Tuesday's After-Market Session","id":124713304,"image":"","symbol":"ONCT","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3273653928"}]}